



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/766,678	01/23/2001	Axel Ullrich	038602/1080 1082

CONFIRMATION NO. 4384

FORMALITIES LETTER



OC00000005951191

Beth A. Burrous
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

Date Mailed: 04/09/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- o The statutory basic filing fee is missing.
Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- o Total additional claim fee(s) for this application is \$1886. 11/13/2001 HDEMESS1 00000008 09766678

□ \$576 for 32 total claims over 20.	01 FC:101	740.00 OP
□ \$1040 for 13 independent claims over 3.	02 FC:102	1092.00 OP
□ \$270 for multiple dependent claim surcharge.	03 FC:103	576.00 OP
	04 FC:104	280.00 OP
	05 FC:105	130.00 OP
- o The oath or declaration is unsigned.
- o To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- o **The balance due by applicant is \$ 2726.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- o Substitute drawings in compliance with 37 CFR 1.84 because:
 - more than one figure is present and each figure is not labeled "Fig." with a consecutive Arabic numeral (1, 2, etc.) or an Arabic numeral and capital letter in the English alphabet (A, B, etc.)(see 37 CFR 1.84(u)(1));



09/766,678 - 11/09/01

- o This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- ▣ For Rules Interpretation, call (703) 308-4216
- ▣ To Purchase PatentIn Software, call (703) 306-2600
- ▣ For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

09756678-10901

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED .
VASCULOGENESIS AND ANGIOGENESIS

Appl. No.: 09/766,678

Filing Date: 01/23/2001

Examiner: unassigned

Art Unit: 1647

TRANSMITTAL OF MISSING PARTS
OF PATENT APPLICATION

Commissioner for Patents
Washington, D.C. 20231

Attn: BOX MISSING PARTS

Sir:

In response to the Notice to File Missing Parts of Application mailed on 04/09/01, in the above-identified application, transmitted herewith are the missing parts needed to complete the filing of the subject patent application.

Enclosed are:

- [X] Declaration and Power of Attorney (4 pages(2 copies @ 2 pages each))
- [X] Return Copy of Notice to File Missing Parts
- [X] Petition for Extension of Time
- [X] Statement Regarding Submission of Sequence Listing
- [X] Paper Copy of Sequence Listing (16 pages)
- [X] Transmittal of Formal Drawings
- [X] 25 Sheets of Drawings (Figures 1 – 17)

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$740.00	\$740.00
Total Claims:	52	- 20	= 32	x \$18.00	= \$576.00
Independents:	16	- 3	= 13	x \$84.00	= \$1,092.00
If any Multiple Dependent Claim(s) present:			+	\$280.00	= \$280.00
Surcharge under 37 CFR 1.16(e) for late filing of Executed Declaration and late payment of filing fee			+	\$130.00	= \$130.00
				SUBTOTAL:	= \$2,818.00
[] Small Entity Fees Apply (subtract ½ of above):					= \$0.00
				TOTAL FILING FEE:	= \$2,818.00
				Five Month Extension of Time	\$1,960.00
				TOTAL FEE	= \$4,778.00
Difference to pay:				\$0.00	= \$4,778.00

[X] Check in the amount of \$4,778.00 in payment of surcharge fee \$130.00 (37 C.F.R. § 1.16(e)), Filing Fee \$740.00, 32 claims in excess of 20 \$576.00, 13 Independent claims in excess of 3 \$1,092.00, Multiple Dependent Claim(s) \$280.00 and Five-Month Petition for Extension of Time \$1,960.00.

[] Please charge Deposit Account No. 19-0741 in the amount of \$0.00 in payment of surcharge fee (37 C.F.R. § 1.16(e))

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date 11/8/01 By Beth A. Burrous

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axel ULLRICH et al.

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND ANGIOGENESIS

Appl. No.: 09/766,678

Filing Date: 01/23/2001

Examiner: unassigned

Art Unit: 1647

TRANSMITTAL OF FORMAL DRAWINGS

Commissioner for Patents
Washington, D.C. 20231

ATTENTION: DRAWING REVIEW BRANCH

Sir:


Transmitted herewith are the formal drawings (25 sheets, Figures 1-17) for the above-identified application. The Official Draftsperson is respectfully requested to approve these drawings for entry into the application.

Respectfully submitted,

Date

11/8/01

By



FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 038602/1082

In re patent application of

Axel ULLRICH et al.

Group Art Unit: 1647

Serial No.: 09/766,678

Examiner: Unassigned

Filed: January 25, 2001

or: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND ANGIOGENESIS



STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING

Commissioner for Patents
Washington, D.C. 20231


Sir:

The computer readable form of the Sequence Listing for this application is to be identical with that filed in Application Number 08/193,829 filed February 9, 1994. In accordance with 37 CFR 1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application on November 4, 1996. It is understood that the United States Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is submitted herewith and instructions are provided in the preliminary amendment for incorporation into the specification.

Respectfully submitted,

11/8/01

Date



Beth A. Burrous
Reg. No. 35,087

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, D.C. 20007-5109
(202) 672-5300